Pfizer Ventures and Apricot Capital led a $61m funding round in Vibrant Therapeutics.

Pfizer Ventures, a venture capital arm, and Apricot Capital, a venture capital firm, led a $61m funding round in Vibrant Therapeutics, a clinical-stage biotechnology company, with participation from Bayland Capital, HSG, Northern Light Venture Capital, and First Principles Capital. “Vibrant represents the type of platform-driven company we seek to support – one that pairs innovative science with a clear path to global development. The company’s logic-gated approach and rapid progress with VIB305 underscore its potential to meaningfully expand the therapeutic window in solid tumors, and we are excited to partner with the team as they enter this next phase of growth,” Arthur Qiang, Ph.D., Apricot Capital Managing Partner.